A Single-Center, Open-Label, Single Oral Dose Phase I Study to Determine the Excretion Balance of Radiocarbon (i.e., the Sum of 14C-Labeled TRO19622 and Its 14C-Metabolites) and to Investigate the Pharmacokinetics and Metabolic Profile of TRO19622
Latest Information Update: 20 Jul 2016
At a glance
- Drugs Olesoxime (Primary)
- Indications Huntington's disease; Multiple sclerosis; Spinal muscular atrophy
- Focus Pharmacokinetics
- Sponsors Roche
- 20 Jul 2016 New trial record